l MIGHTYLION,the 'big question'.
Are we experiencing a situation where the Camofi matter is ostensibly behind us, ostensibly satisfied by ACTC, and all in good shape until Camofi's minimal 1.2m payment due next year or jsy experiencing a bunch of believers,salivating at this incredibly cheap share price,prior to what is anticipated o be and explosive journal clinical data presentation and resulting peer review accolades (already appearing as a 'scoop'in numerous print data)?
Disclosure. Earlier posting that I had sold a part of my position on the default news,I'm now almost totally back in.
